For the fourth quarter of 2007, Alimta generated sales of $244.1 million, an increase of 42 percent compared with the fourth quarter of 2006. U.S. sales of Alimta increased 33 percent, to $125.8 million, due primarily to increased demand, while sales outside the U.S. increased 54 percent, to $118.3 million, due primarily to increased demand and the favorable impact of foreign exchange rates.
For the full year of 2007, worldwide Alimta sales increased 40 percent, to $854.0 million. U.S. Alimta sales for 2007 were $448.0 million, a 28 percent increase driven by increased demand and, to a lesser extent, higher prices. Alimta sales outside the U.S. were $406.0 million, a 55 percent increase, driven by increased demand and favorable exchange rates.
Fourth-quarter sales of Forteo were $198.2 million, a 15 percent increase compared with the fourth quarter of 2006. U.S. sales of Forteo increased 12 percent, to $138.4 million, driven primarily by higher prices, partially offset by lower volume caused by variations in wholesaler buying patterns. Sales outside the U.S. grew 24 percent, to $59.8 million, due to the favorable impact of foreign exchange rates and higher demand.
For the full year of 2007, worldwide Forteo sales increased 19 percent, to $709.3 million. U.S. Forteo sales for 2007 were $494.1 million, a 19 percent increase driven by higher net selling prices. U.S. sales growth benefited from access to medical coverage through the Medicare Part D program, decreased utilization of the company's U.S. patient assistance program and, to a lesser extent, increased demand. Forteo sales outside the U.S. were $215.2 million, a 21 percent increase, driven by increased demand and favorable exchange rates.
During the fourth quarter of 2007, Strattera generated
|SOURCE Eli Lilly and Company|
Copyright©2008 PR Newswire.
All rights reserved